The failure of the three tumor cell lines to respond significantly upon DMXAA treatment can be attributed to a lack of type I IFN, suggesting that even with a permeable STING agonist, the extensive defects in their STING pathway rendered the tumor cell lines incapable of expressing significant quantities of type I IFN. The gene discussed is STING1; the disease is neoplasm.